title: [Nine-year experience in the treatment of patients with diffuse large B-cell lymphosarcoma].
abstract: OBJECTIVE
  To ascertain indications to standard (CHOP-21/R-CHOP-21) and intensive (mNHL-BFM-90) treatment in patients with diffuse large B-cell lymphosarcoma (DLBCL) with involvement of lymphoid organs.
  
  
  METHODS
  The trial, performed from January 2002 to December 2010, enrolled 139 DLBCL patients with affected lymph nodes (LN), tonsils, spleen, bone marrow (BM). The diagnosis was made according to WHO criteria. The patients were examined according to the protocol of lymphoproliferative diseases. Biopsy material from all 139 patients was studied immunohistochemically on paraffin blocks (LN, tonsils, spleen, BM) using a wide panel of antibodies. The same examinations of BM were made in all 18 cases of BM involvement. Cytogenetic examination was performed in 106 patients: 48 standard cytogenetic tests, 139 - FISH for t (14;18) as well as rearrangement of locus 3q27. Patients with a poor prognosis (n = 86, 61.8%) received intensive therapy according to mNHL-BFM-90 program. The signs of a poor prognosis were the following: massive tumor (tumor size more than 7.5 cm), invasion into the adjacent organs or tissues, stage III-IV disease by Enn-Erbor, high concentration of LDG. Patients without a poor prognosis (n = 53, 38.2%) received standard treatment CHOP-21 (n = 28) or R-CHOP-21 (n = 25).
  
  
  RESULTS
  A complete remission without recurrences was achieved in all 53 patients without signs of unfavourable prognosis (100%). Overall 5-year survival was 96%, 2 patients died in remission of other causes. Of 86 patients with a poor prognosis a complete remission was achieved in 64 (74.4%) patients. Overall and recurrence-free 5-year survival was 65 and 86%, respectively.
  
  
  CONCLUSIONS
  Standard treatment provided long-term complete remission in all the patients without poor prognosis. Intensive (mNHL-BFM-90) treatment produced the best results in generalized lesion without BM involvement. Overall 5-year survival was 84% in these patients and 12% in patients with BM involvement.
authors: A U
authors: AU
authors: Magomedova
authors: S K
authors: SK
authors: Kravchenko
authors: A M
authors: AM
authors: Kremenetskaia
authors: E A
authors: EA
authors: Zvonkov
authors: E A
authors: EA
authors: Bariakh
authors: Ia K
authors: IaK
authors: Mangasarova
authors: I B
authors: IB
authors: Kaplanskaia
authors: R S
authors: RS
authors: Samoĭlova
authors: I A
authors: IA
authors: Vorob'ev
authors: T N
authors: TN
authors: Obukhova
authors: S R
authors: SR
authors: Karagiulian
authors: E M
authors: EM
authors: Shulutko
authors: G M
authors: GM
authors: Galstian
authors: D S
authors: DS
authors: Mar'in
authors: N G
authors: NG
authors: Gabeeva
authors: A I
authors: AI
authors: Vorob'ev
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013156:Splenectomy; D016896:Treatment Outcome; D055815:Young Adult